| Name | Title | Contact Details |
|---|
National General is an insurance holding company that offers auto, RV and home insurance products and services to individuals and businesses.
Fisher Barton is a prominent manufacturing company with over 50 years of experience, founded in 1973 by metallurgist Richard L. Wilkey. Headquartered in Watertown, Wisconsin, the company has grown to employ more than 900 people worldwide. It operates as a group of independent manufacturing companies, including Fisher Barton Blades and Thermal Spray Technologies. The company specializes in materials and surface engineering, offering a diverse range of products such as industrial knives, lawnmower blades, agricultural knives, and thermal spray coatings. Fisher Barton is recognized for its metallurgical expertise, supported by an in-house lab that enhances product development and quality assurance. The company serves major clients, including John Deere, and has been acknowledged for its excellence in supply and innovation. Fisher Barton continues to focus on technological advancements and employee development to maintain its leadership in the industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.